Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01093703 · ClinicalTrials.gov registry record · NA

Chronotherapy Versus Conventional BP Control to Correct Abnormal Circadian BP Pattern in Kidney Transplant Recipients

A NA study, sponsored by Mayo Clinic.

Completed
Registry status
NA
Development phase
99
Enrollment target

NCT01093703: Completed NA study, sponsored by Mayo Clinic.

NCT01093703 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 99 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01093703, a NA study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
NA
Development phase
99 participants
Enrollment target

Study Summary

The purpose of this study is to identify and manage factors related to blood pressure control that impact organ function and survival in kidney transplant recipients. Loss of the circadian (relating to a 24-hour rhythm) blood pressure pattern is common in kidney transplant recipients and is associated with poor allograft kidney function. It is still unclear if restoring the normal day-night blood pressure (BP) pattern will translate into better allograft outcome. Although studies in patients with and without chronic kidney disease indicate that restoration of the normal nocturnal (night) dipping in BP is possible by changing the timing of the BP medications to cover the overnight period (chronotherapy), this has not been tested in kidney transplant patients.

Interventions

  • OTHER Medication Adjustment

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2008-12
Est. Completion 2012-11
Phase NA
Mayo Clinic

2,844 total trials

What the finished NCT01093703 record still lists

NCT01093703 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 1 intervention - of which Medication Adjustment is the first listed.

NCT01093703 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01093703 about?

NCT01093703 is a clinical study titled "Chronotherapy Versus Conventional BP Control to Correct Abnormal Circadian BP Pattern in Kidney Transplant Recipients". The purpose of this study is to identify and manage factors related to blood pressure control that impact organ function and survival in kidney transplant recipients. Loss of the circadian (relating to a 24-hour rhythm) blood pressure pattern is common in kidney transplant recipients and is associat...

What is the current status of trial NCT01093703?

This trial is currently completed. It is a NA study. The enrollment target is 99 participants. The study started on 2008-12. Estimated completion is 2012-11.

What interventions are being tested in trial NCT01093703?

The interventions under investigation include: Medication Adjustment (OTHER).

Who is sponsoring clinical trial NCT01093703?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01093703's enrollment target sits among peer trials

99 920th of 2000 higher than 1,079 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03965234 · 99 participants · Phase 1

    Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

  • NCT04022616 · 99 participants

    Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients

  • NCT04042844 · 99 participants · Phase 2

    A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

  • NCT04143724 · 99 participants · Phase 2

    Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01093703, the US trial registry maintained by the National Library of Medicine. NCT01093703 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.